The team behind OssiGel
Founded 2024 · Sweden · TRL4 · University of Basel origin
Dhalion Biotech AB was founded in Lund, Sweden, by researchers from Lund University with one goal: to bring OssiGel to patients. OssiGel is an off-the-shelf, cell-free bone graft developed through developmental engineering, a living-inspired approach that mimics how bone naturally forms in the body.
Our mission
We hijack the body's own blueprint for growing bone, so no patient has to choose between a risky graft and a healing that never comes.
Our story
Dhalion Biotech spun out of research at the University of Basel in December 2024, consolidating the OssiGel IP and technology under a single commercial entity. The company is headquartered in Sweden, building on peer-reviewed science published in PNAS, Advanced Materials and Acta Biomaterialia.
Backed by
Dhalion's work has been supported by a Starting Grant (2020), two Proof of Concept grants (2022, 2025) and a €2.5M EIC Transition grant (2026), funded by the European Union.
